Frontiers in adjuvant therapy in stage II-III melanoma

被引：0
|
作者：
Eggermont, AMM [1 ]
机构：
[1] Univ Rotterdam Hosp, Dr Daniel Den Hoed Canc Ctr, Dept Surg Oncol, NL-3075 EA Rotterdam, Netherlands
来源：
TUMORI JOURNAL | 2001年 / 87卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S60 / S63
页数：4
相关论文
共 50 条
  • [1] Does adjuvant systemic therapy with interferon-α for stage II-III melanoma prolong survival?
    Eggermont, AMM
    Punt, CJA
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2003, 4 (08) : 531 - 536
  • [2] Adjuvant treatment with interferon-α in melanoma stage II-III:: Experience of melanoma cooperative group
    Ascierto, PA
    Daponte, A
    Parasole, R
    Palmieri, G
    Mozzillo, N
    Castello, G
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S374 - S375
  • [3] Timing of adjuvant therapy in stage II-III colorectal cancer.
    dos Santos, Lucas Vieira
    Faria, Thaissa Veiga
    Lima, Andre Bacellar Costa
    Abdalla, Kathia Cristina
    Viana, Vivian de Araujo
    Tavares, Isabela R.
    de Moraes, Eduardo Dias
    Melani, Armando
    Cruz, Marcelo Rocha
    Lima, Joao Paulo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy
    Suciu, Stefan
    Eggermont, Alexander M. M.
    Lorigan, Paul
    Kirkwood, John M.
    Markovic, Svetomir N.
    Garbe, Claus
    Cameron, David
    Kotapati, Srividya
    Chen, Tai-Tsang
    Wheatley, Keith
    Ives, Natalie
    de Schaetzen, Gaetan
    Efendi, Achmad
    Buyse, Marc
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (01): : 87 - 96
  • [5] Adjuvant multi-peptide vaccination in high risk stage II-III melanoma patients
    Filipazzi, Paola
    Cova, Agata
    Sovena, Gloria
    Squarcina, Paola
    Pilla, Lorenzo
    Patuzzo, Roberto
    Maurichi, Andrea
    Cutolo, Gianluca
    Castelli, Chiara
    Casati, Chiara
    Tragni, Gabrina
    Deho, Paola
    Santinami, Mario
    Parmiani, Giorgio
    Rivoltini, Licia
    JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) : 894 - 894
  • [6] Prognostic biomarkers in stage II-III melanoma.
    Rizk, Emanuelle M.
    Gartrell, Robyn D.
    Chen, Andrew
    Chang, Rui
    Marks, Douglas K.
    Esancy, Camden L.
    Taback, Bret
    Horst, Basil A.
    Drake, Charles G.
    Rabadan, Raul
    Saenger, Yvonne M.
    CANCER RESEARCH, 2020, 80 (19) : 49 - 50
  • [7] Neoadjuvant or adjuvant chemoradiation therapy for stage II-III esophageal squamous cell carcinoma.
    Chen, Yongshun
    Hao, Daxuan
    Wu, Xiaoyuan
    Yang, Yuanyuan
    He, Chunyu
    Wang, Wen
    Liu, Jinsong
    Wang, Jianhua
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [8] Considering adjuvant therapy for stage II melanoma
    Poklepovic, Andrew S.
    Luke, Jason J.
    CANCER, 2020, 126 (06) : 1166 - 1174
  • [9] The role of adjuvant radiation in stage II-III endometrial stromal sarcoma
    Lander, Megan
    Lesnock, Jamie
    Vargo, John
    Taylor, Sarah
    Courtney-Brooks, Madeleine
    Sukumvanich, Paniti
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S414 - S414
  • [10] Characterization of the immune landscape in stage II-III melanoma using qIF
    Gartrell, Robyn
    Marks, Douglas
    Stack, Edward C.
    Lu, Yan
    Hart, Thomas D.
    Gerard, Camille
    Esancy, Camden
    Jia, Dan Tong
    Armenta, Paul
    Izaki, Daisuke
    Davari, Danielle
    White-Stern, Ashley
    Blake, Zoe
    Fu, Yichun
    Horst, Basil
    Saenger, Yvonne
    CANCER RESEARCH, 2017, 77
12345